Best Healthcare Market Research Companies in Turkey (2026 Guide)
An independent guide to the leading healthcare market research companies operating in Turkey for 2026. This guide profiles 5 specialist firms across pharmaceutical primary research, TITCK regulatory expertise, SGK payer research, physician and KOL engagement, and HEOR — comparing capabilities and Turkey-specific expertise to help you select the right healthcare research partner in one of the region's largest and most strategically significant pharmaceutical markets bridging Europe and MENA.
Published 2026-06-11 · By BioNixus Research Team
5
Firms Profiled
$25B+
Pharma Market
TITCK-Regulated
Hub
8
FAQs Answered
Best Healthcare Market Research Companies in Turkey (2026)
The following healthcare market research companies have demonstrated operations or project delivery in Turkey as of 2026, covering pharmaceutical primary research, TITCK/SGK regulatory and payer support, HEOR, and physician and patient research:
- 1BioNixus — Best for: pharmaceutical U&A, KOL mapping, physician surveys, TITCK/SGK regulatory and market access support, payer research, HEOR, Turkish-English bilingual research, and Turkey's strategic bridge role between Europe and MENA
- 2IQVIA Turkey — Best for: IMS Turkey pharma prescription data, Turkish RWE, sales force effectiveness, and TITCK regulatory analytics
- 3Ipsos Turkey — Best for: large-scale quantitative research capability in Turkey, HCP surveys, patient research, and Turkish consumer health studies
- 4Kantar Turkey (Kantar Insight) — Best for: Turkish consumer research, patient tracking, health behaviour studies, and brand health across Turkey
- 5NielsenIQ Turkey — Best for: Turkish consumer tracking, retail measurement, OTC/consumer health data, and Turkish market share analytics
Turkey Healthcare Market Research Landscape 2026
Turkey is one of the largest pharmaceutical markets in the Europe-MENA region, valued at over $25 billion, anchored by a major pharma and healthcare cluster in Istanbul with significant manufacturer and distributor presence. Turkey's Universal Health Coverage programme — implemented fully since 2008 under the Health Transformation Programme — dramatically expanded access to medicines and healthcare services, creating a large and growing pharmaceutical market. The country hosts a strong domestic generic pharmaceutical manufacturing sector, led by companies such as Abdi İbrahim, İlko İlaç, and Eczacıbaşı — making competitive intelligence and formulary research particularly important for multinational entrants.
Turkey's pharmaceutical regulatory framework is governed by TITCK (Türkiye İlaç ve Tıbbi Cihaz Kurumu — the Turkish Medicines and Medical Devices Agency), which oversees product authorisation, pharmacovigilance, and clinical trial approval. SGK (Sosyal Güvenlik Kurumu — the Social Security Institution) is the dominant payer, responsible for the reimbursement list (ödeme listesi) that determines SGK-funded medicine access. Understanding TITCK registration requirements and SGK reimbursement criteria is essential for any pharmaceutical market access strategy in Turkey. TÜIK (Türkiye İstatistik Kurumu — the Turkish Statistical Institute) provides healthcare utilisation and epidemiological data that underpins market sizing.
Turkey occupies a unique strategic bridge position between European and MENA pharmaceutical markets. Istanbul's position as both a European and Asian city creates a dual-market dynamic: Turkey serves as a regional hub for companies seeking to understand both Balkan/Eastern European and Middle Eastern market dynamics. Turkey's large physician network — approximately 200,000 registered physicians with TITCK, supported by a significant resident and specialist training infrastructure — offers outstanding access for pharmaceutical primary research. Turkish-English bilingual research capability, combined with deep TITCK/SGK regulatory knowledge, is essential for effective healthcare market research in this market.
5 Healthcare Market Research Companies in Turkey (2026)
Firms are assessed by use case and market positioning — select based on your research type, sector, and in-country requirements.
BioNixus
Best for: pharmaceutical U&A, KOL mapping, physician surveys, TITCK/SGK regulatory and market access support, payer research, HEOR, Turkish-English bilingual research, and Turkey's strategic bridge role between Europe and MENA
BioNixus is a global healthcare market research and insights firm headquartered in the USA with offices in the UK and Middle East, delivering specialist pharmaceutical and healthcare research across Turkey and the broader Europe-MENA corridor. With 15+ years of experience serving 48+ global clients across 17+ countries, BioNixus brings deep Turkey market expertise to every engagement — from Turkish physician and KOL surveys to TITCK-aligned regulatory research and SGK payer research. BioNixus is fluent in Turkey's healthcare regulatory landscape: TITCK product authorisation and clinical trial frameworks, SGK reimbursement list dynamics, the influence of domestic generic manufacturers on formulary competition, and the strategic implications of Turkey's bridge position between EU and MENA markets. The firm recruits across Turkey's large specialist physician community and maintains established relationships with Turkish KOLs in oncology, cardiology, and other major therapeutic areas. Turkish-English bilingual fieldwork execution, SGK payer stakeholder research, and Turkey-MENA regional intelligence are core capabilities that position BioNixus as the preferred full-service healthcare research partner for pharmaceutical companies operating in or entering the Turkish market.
Key strengths
- Pharmaceutical U&A, brand tracking, and market access research in Turkey
- TITCK regulatory intelligence and SGK reimbursement research support
- Physician surveys and KOL mapping across Turkey's large specialist networks
- SGK payer research and Turkish reimbursement list (ödeme listesi) analysis
- HEOR, patient journey, and health economics research for Turkish market
- Turkish-English bilingual execution bridging Europe-MENA market intelligence
IQVIA Turkey
Best for: IMS Turkey pharma prescription data, Turkish RWE, sales force effectiveness, and TITCK regulatory analytics
IQVIA has a strong Turkey presence with Istanbul offices, providing healthcare data, analytics, and clinical research services to pharmaceutical companies in the Turkish market. Their Turkey prescription data (IMS Turkey heritage), TITCK regulatory intelligence, and real-world evidence capabilities are widely used for commercial launch planning and market access strategy. IQVIA Turkey supports technology-enabled clinical trials and regulatory strategy through TITCK-aligned study design. Their primary strength lies in pharmaceutical data and analytics at scale rather than qualitative or stakeholder-driven primary research.
Key strengths
- Turkey prescription data and pharmaceutical audit (IMS Turkey heritage)
- TITCK regulatory intelligence and Turkish RWE
- Technology-enabled clinical trial and CRO services in Turkey
- Sales force effectiveness and commercial analytics for Turkish market
Ipsos Turkey
Best for: large-scale quantitative research capability in Turkey, HCP surveys, patient research, and Turkish consumer health studies
Ipsos has a substantial Turkey operation and is one of the largest market research firms in the Turkish market, with deep quantitative survey infrastructure serving both consumer and healthcare clients. Their Turkey capability covers physician and patient surveys, consumer health research, message testing, and concept evaluation for the Turkish market. Ipsos Turkey leverages large national survey panels and is an established partner for multinational pharmaceutical clients requiring standardised European methodologies with Turkish local execution and Turkish-language instruments.
Key strengths
- Large-scale HCP and patient quantitative surveys in Turkey
- Strong Turkish survey panel and fieldwork infrastructure
- Consumer health and patient research for Turkish market
- Message testing and concept evaluation for Turkish pharmaceutical clients
Kantar Turkey (Kantar Insight)
Best for: Turkish consumer research, patient tracking, health behaviour studies, and brand health across Turkey
Kantar Turkey operates a strong consumer research practice covering Turkish consumer insights, brand health tracking, and media effectiveness. Their healthcare research capability builds on this substantial Turkish consumer research infrastructure, primarily serving OTC and consumer health brands. Kantar Turkey is less focused on specialist pharmaceutical primary research and TITCK/SGK HTA support than dedicated pharma research agencies, but their large Turkish consumer panel and longitudinal tracking capability provide value for consumer health and over-the-counter medicine research.
Key strengths
- Large Turkish consumer research panel and longitudinal tracking
- Consumer health and OTC product research for Turkey
- Brand health and advertising effectiveness in Turkey
- Turkish consumer behaviour and health attitude studies
NielsenIQ Turkey
Best for: Turkish consumer tracking, retail measurement, OTC/consumer health data, and Turkish market share analytics
NielsenIQ operates in Turkey providing retail measurement and consumer intelligence for FMCG, OTC, and consumer health categories. Their Turkey retail audit and consumer tracking capabilities serve consumer goods companies with point-of-sale data and shopper behaviour studies across Turkish modern trade. For pharmaceutical clients, NielsenIQ Turkey's value is primarily in OTC and consumer health category tracking and market sizing — rather than prescription pharmaceutical or clinical market research. Their data is widely used as a secondary source for Turkish consumer health market intelligence.
Key strengths
- Turkey retail measurement and modern trade data
- OTC and consumer health category tracking for Turkish market
- Turkish consumer behaviour and shopper analytics
- Turkish market share data for FMCG and consumer health categories
Turkey Healthcare Market Research Capabilities Comparison
| Capability | BioNixus | IQVIA Turkey | Ipsos Turkey | Kantar Turkey | NielsenIQ Turkey |
|---|---|---|---|---|---|
| Pharmaceutical primary research (qual + quant) | Full-service | Selective / analytics-led | Full-service | Limited pharma focus | OTC/consumer only |
| TITCK/SGK HTA support and payer research | Core capability | Analytics / regulatory data | Partial | Limited | No |
| Physician and KOL recruitment (Turkey) | Yes | Yes (data-driven) | Yes | Limited | No |
| SGK reimbursement list research | Yes | Yes (data analytics) | Partial | No | No |
| Turkish-English bilingual execution | Standard | Standard | Standard | Standard | Turkish-primary |
| Europe-MENA bridge market intelligence | Yes | Partial | Limited | No | No |
Key Considerations for Turkey Healthcare Market Research
TITCK and SGK Regulatory and Payer Context
TITCK (Türkiye İlaç ve Tıbbi Cihaz Kurumu) governs all pharmaceutical product authorisation, clinical trial approval, pharmacovigilance, and promotional activity in Turkey. SGK (Sosyal Güvenlik Kurumu) is Turkey's dominant payer, maintaining the ödeme listesi (reimbursement list) that determines which medicines are funded under Turkey's Universal Health Coverage system. SGK reimbursement decisions involve both therapeutic and economic criteria, and the SGK negotiation process for innovative medicines creates a distinct payer engagement challenge. Research partners must understand TITCK compliance requirements for non-interventional studies and physician interactions, and SGK's evidence requirements for positive listing decisions.
Turkey's Strategic Bridge Position Between Europe and MENA
Turkey occupies a unique geographic and strategic position bridging European and MENA pharmaceutical markets. Many multinational pharmaceutical companies use Turkey as a regional hub for Balkan, Caucasus, and MENA market coordination. Istanbul's healthcare infrastructure — major teaching hospitals, university medical centres, and private hospital groups including Memorial Health Group and Acıbadem Hospitals — serves as a reference centre for surrounding markets. Research conducted in Turkey often informs broader regional strategies. Turkish KOLs in oncology, cardiology, and endocrinology carry regional influence beyond Turkish borders, making Turkey an important market for international advisory and evidence generation.
Bilingual Turkish-English Research and Large Physician Network
Turkey has approximately 200,000 registered physicians, with a large proportion having completed specialist training in European or North American institutions — creating a highly qualified and internationally engaged physician population accessible for market research. Turkish-English bilingual research execution is standard for multinational pharma, but Turkish-language instruments remain essential for comprehensive HCP and patient sampling. Turkey's growing clinical trial sector, supported by TITCK's streamlined study approval process, provides additional primary research infrastructure for pharmaceutical companies. The country's strong generic manufacturing sector and active biosimilar market also create ongoing demand for competitive intelligence and formulary dynamics research.
Frequently Asked Questions
What are the best healthcare market research companies in Turkey?
Leading healthcare market research companies in Turkey include BioNixus, IQVIA Turkey, Ipsos Turkey, Kantar Turkey, and NielsenIQ Turkey. BioNixus is a global healthcare market research firm with Turkey execution capability, covering pharmaceutical primary research, TITCK/SGK regulatory and payer support, physician surveys, KOL mapping, and Turkish-English bilingual HEOR research.
How much does healthcare market research cost in Turkey?
Custom healthcare market research in Turkey typically ranges from $12,000 to $55,000 per project depending on methodology, therapeutic area, and scope. Qualitative KOL advisory boards typically cost $15,000–$35,000, while large-scale quantitative physician surveys or HEOR studies may reach $35,000–$70,000+. SGK-aligned market access evidence research varies in cost based on complexity and the scope of payer stakeholder engagement required.
Which company is best for TITCK/SGK regulatory and payer research in Turkey?
BioNixus specialises in TITCK/SGK-aligned healthcare market research including Turkish payer qualitative interviews, SGK reimbursement list research, and Turkish HCP evidence generation. Their understanding of TITCK product authorisation processes, SGK ödeme listesi dynamics, and Turkey's domestic generic manufacturer competitive landscape positions them as a specialist partner for Turkey pharmaceutical market access evidence.
How do I recruit physicians for market research studies in Turkey?
Physician recruitment in Turkey requires established professional networks across major university hospitals, state hospital networks, and private hospital groups including Memorial and Acıbadem. BioNixus maintains Turkey physician and KOL recruitment networks across major therapeutic areas including oncology, cardiology, and endocrinology. TITCK compliance requirements for non-interventional studies and physician interaction protocols must be observed. Turkish physicians are highly accessible and many are fluent in English.
What is TITCK and why does it matter for pharmaceutical companies in Turkey?
TITCK (Türkiye İlaç ve Tıbbi Cihaz Kurumu — Turkish Medicines and Medical Devices Agency) is Turkey's national medicines and medical devices regulatory authority. TITCK governs product authorisation, clinical trial approval, pharmacovigilance, and promotional activity compliance. For pharmaceutical companies, TITCK authorisation is the prerequisite for market entry, and TITCK's non-interventional study approval process governs how market research involving patient data or physician interactions is conducted in Turkey.
What is SGK and how does it affect pharmaceutical reimbursement in Turkey?
SGK (Sosyal Güvenlik Kurumu — Social Security Institution) is Turkey's primary public payer, responsible for the national reimbursement list (ödeme listesi) under the Universal Health Coverage system. SGK coverage extends to approximately 90% of Turkey's population, making SGK reimbursement the critical gateway to broad market access. SGK evaluates new medicines based on clinical efficacy, safety, and economic criteria, and its negotiation process for innovative and high-cost medicines is a key market access challenge requiring robust evidence-based payer research.
What is the Turkish pharmaceutical market size?
The Turkish pharmaceutical market is valued at over $25 billion, making it one of the largest in the Europe-MENA region. Turkey has a significant domestic generic pharmaceutical manufacturing sector led by Abdi İbrahim, İlko İlaç, and Eczacıbaşı, alongside major multinational presence. Turkey's Universal Health Coverage expansion since 2008 has driven consistent volume growth, and the country's growing biosimilars market creates additional competitive dynamics for originators and biosimilar manufacturers alike.
Does BioNixus conduct healthcare market research in Turkey?
Yes. BioNixus is a global healthcare market research firm with Turkey delivery capability, serving pharmaceutical and biotech clients across the Turkish market. Turkey services include physician surveys, KOL mapping, TITCK/SGK payer research, HEOR, patient journey studies, and Turkish-English bilingual fieldwork. BioNixus also provides Turkey-to-MENA bridge market intelligence for companies managing regional pharmaceutical strategies. Contact us to discuss your Turkey healthcare research requirements.
Plan Healthcare Market Research in Turkey
BioNixus delivers specialist healthcare market research across Turkey and the Europe-MENA corridor — pharmaceutical primary research, TITCK/SGK regulatory and payer evidence, physician and KOL surveys, HEOR, Turkish-English bilingual fieldwork, and Turkey-to-MENA regional intelligence for pharma and biotech companies.
Request a Proposal